newsfilter
← Earnings
Earnings Releases·

Cencora — Fiscal 2026 Fourth Quarter Earnings Summary

  • Fiscal 2026 revenue reached $337.4 billion (up 5.0% YoY), while GAAP diluted EPS surged 125.5% to $17.95 and Adjusted diluted EPS rose 12.3% to $17.97; Q4 2026 Adjusted Free Cash Flow was approximately $3.8 billion.
  • Management raised Fiscal 2027 Adjusted Diluted EPS guidance to $19.40–$19.75 (8%–10% growth) and projected revenue growth of 3%–5%, contingent on the Q1 2027 closing of the Profarma equity sale and the March 31, 2027, MWI Animal Health merger.
  • Strategic capital allocation included a 10% dividend increase to $0.66 per share, $910 million in capital expenditures, and 1.1% share repurchases in Q4, alongside the signing of a definitive agreement to acquire American Oncology Network.
  • The company announced a new reporting structure effective Q1 Fiscal 2027, consolidating segments into Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other, with long-term targets of 10%–14% Adjusted Diluted EPS growth.
Company
CENCORA INC
Sector
Healthcare
Industry
Medical Distribution